Sign In
Buy ZLAB
$18.49
+0.0100 (+0.0541%)
At Close: Jun 23, 2026
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
07:00am, Tuesday, 16'th Jun 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug p
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License
Zai Lab Announces Changes to Senior Leadership Team
06:09pm, Thursday, 21'st May 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and effici
Zai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attached
09:57am, Wednesday, 13'th May 2026
Zai Lab faces stalling growth in Greater China due to price controls and declining Zejula revenues, shifting focus to global pipeline assets. I assign zero intrinsic value to ZLAB's China business, gi
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug
Zai Lab Q1 Earnings Call Highlights
05:07am, Saturday, 09'th May 2026
Zai Lab NASDAQ: ZLAB reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology a
Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript
10:41pm, Thursday, 07'th May 2026
Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
10:31am, Thursday, 07'th May 2026
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
06:00am, Thursday, 07'th May 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corpo
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
07:30am, Wednesday, 22'nd Apr 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2026 financial results and provide recent corporate updat
Zai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases Transcript
Zai Lab (NASDAQ:ZLAB) Sees Strong Trading Volume – Still a Buy?
03:59am, Sunday, 19'th Apr 2026
Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) saw unusually-strong trading volume on Friday. Approximately 632,305 shares were traded during mid-day trading, a decline of 16% from t
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the company's internally devel
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting anti
Ingelheim, Germany and Shanghai , China /Cambridge, Mass. – 15 April , 202 6 – Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) today announced a clinical collaboration
